v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash flows from operating activities:    
Net loss attributable to INVO Fertility, Inc. $ (23,323,054) $ (9,258,953)
Adjustments to reconcile net loss to net cash used in operating activities:    
Non-cash stock compensation issued for services 1,290,482 1,246,765
Non-cash stock compensation issued to directors and/or employees 153
Fair value of stock options issued to employees 178,729 342,728
Non-cash compensation for services 135,000 180,000
Amortization of discount on notes payable 1,182,979 622,283
Impairment loss 16,042,422
Reserve on other assets 498,592
(Gain) Loss from equity method investment (31,294) (9,045)
Loss from debt extinguishment 2,135,854 40,491
Loss on disposal of fixed assets 511,663
Gain on lease termination (94,551)
Loss on disposition 1,534,517
Loss on issuance of warrants 943,862
Gain on changes in fair value (5,172,006)
Gain on settlement (929,500)
Depreciation and amortization 677,364 919,603
Changes in assets and liabilities:    
Accounts receivable (104,155) 27,442
Inventory (5,489) 44,743
Prepaid expenses and other current assets (120,472) (163,761)
Equity investments 4,534
Accounts payable and accrued expenses (1,322,698) 1,350,675
Accrued compensation (153,265) 274,665
Deferred revenue 119,538 193,590
Other current liabilities (60,000)
Leasehold liability 10,721 (35,904)
Accrued interest 119,095 166,772
Deferred tax liabilities (163,115) 163,115
Net cash used in operating activities (7,014,485) (2,974,400)
Cash used in investing activities:    
Payments to acquire property, plant, and equipment (43,412) (183,703)
Proceeds from sale of fixed assets 75,590
Cash acquired in acquisition 472,008
Divesture of NTI (6,569)
Payment for acquisitions (2,695,500)
Net cash used in investing activities (2,745,481) 363,895
Cash from financing activities:    
Proceeds from notes payable 1,344,250
Proceeds from the sale of common stock, net of offering costs 12,355,607 165,131
Proceeds from the sale of preferred stock 2,850,000 1,643,904
Proceeds from warrant exercise 1,110,604 900,611
Preferred stock redemption (4,000,000)
Principal payments on notes payable (1,219,799) (934,419)
Net cash provided by financing activities 11,096,412 3,119,477
Increase in cash and cash equivalents 1,336,446 508,972
Cash and cash equivalents at beginning of period 741,396 232,424
Cash and cash equivalents at end of period 2,077,842 741,396
Supplemental disclosure of cash flow information:    
Interest 644,158 214,742
Taxes
Noncash activities:    
Fair value of preferred stock issued for acquisition 25,148,000
Common stock and preferred stock issued upon conversion notes payable and accrued interest 5,047,044 387,033
Dividends on preferred stock 718,616
Deemed dividend 1,088,554 250,635
Fair value of warrants issued with debt 167,863 188,755
C-2 to common stock exchange 13,735,811
Preferred stock redemption adjustment 521,922
Preferred stock exchange 1,188,000
Common stock issued for accounts payable $ 23,460